Contemporary benefit‐harm profile over two decades in primary prophylactic ICD‐therapy
Authors:
Open Access
- 17 July 2019
- journal article
- research article
- Published by Wiley in Clinical Cardiology
- Vol. 42 (10) , 866-872
Abstract
Background: Implantable cardioverter defibrillator (ICD) was implemented into clinical routine more than 20 years ago. Since then, ICD therapy became standard therapy for primary and secondary prevention of sudden cardiac death in clinical practice.Objectives: Aim of the study was to evaluate the benefit‐harm profile of contemporary primary prophylactic ICD therapy.Methods: A total of 1222 consecutive patients of a prospective single‐center ICD‐registry were analyzed who underwent primary prophylactic ICD implantation between 2000 and 2017. Patients were divided into two groups according to the implantation year: 2010‐2017 (group 1, n = 579) and 2000‐2009 (group 2, n = 643).Results: The rate of estimated appropriate ICD therapy after 8 years was 51% in the 2000s and 42% in the 2010s (P < .001). The complication rate changed slightly from 53% to 47% (P = .005). This decline was mainly driven by the reduction of inappropriate ICD shocks (30% vs 14%, P < .001) whereas the rate of ICD shock lead malfunction and device/ lead infection remained unchanged over time. Nonischemic cardiomyopathy was an independent predictor for ICD complications without benefit of ICD therapy (HR 1.37, 95% CI 1.07‐1.77).Conclusion: The ICD therapy rate for ventricular arrhythmias in patients with primary prophylactic ICD implantation is decreasing over the last two decades. Complication rate remains high due to an unchanged rate of ICD shock malfunctions and device infections. Nonischemic cardiomyopathy is an independent predictor for ICD complications without benefit of ICD therapy in primary prophylactic ICD‐therapy.Keywords
This publication has 25 references indexed in Scilit:
- Impact of prolonged implantable cardioverter-defibrillator arrhythmia detection times on outcomes: A meta-analysisHeart Rhythm, 2014
- Impact of Programming Strategies Aimed at Reducing Nonessential Implantable Cardioverter Defibrillator Therapies on MortalityCirculation: Arrhythmia and Electrophysiology, 2014
- Are Hospitalized or Ambulatory Patients with Heart Failure Treated in Accordance with European Society of Cardiology Guidelines? Evidence from 12 440 Patients of the ESC Heart Failure Long-Term RegistryEuropean Journal of Heart Failure, 2013
- Reduction in Inappropriate Therapy and Mortality through ICD ProgrammingNew England Journal of Medicine, 2012
- Clinical Predictors of Fidelis Lead FailureCirculation, 2012
- Prevalence of bacterial colonization of generator pockets in implantable cardioverter defibrillator patients without signs of infection undergoing generator replacement or lead revisionEP Europace, 2009
- Sensing Failure Associated with the Medtronic Sprint Fidelis Defibrillator LeadJournal of Cardiovascular Electrophysiology, 2007
- Annual Rate of Transvenous Defibrillation Lead Defects in Implantable Cardioverter-Defibrillators Over a Period of >10 YearsCirculation, 2007
- Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart FailureNew England Journal of Medicine, 2005
- Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection FractionNew England Journal of Medicine, 2002